Dynamic Changes in Neutrophil-to-Lymphocyte Ratio are Associated with Survival and Liver Toxicity Following Stereotactic Body Radiotherapy for Hepatocellular Carcinoma

References

• Pinero F, Dirchwolf M, Pessoa MG. Biomarkers in hepatocellular carcinoma: diagnosis, prognosis and treatment response assessment. Cells. 2020;9(6):1370. doi:10.3390/cells9061370
   PubMed Web of Science ®Google Scholar
• Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883–899. doi:10.1016/j.cell.2010.01.025
   PubMed Web of Science ®Google Scholar
• Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436–444. doi:10.1038/nature07205
   PubMed Web of Science ®Google Scholar
• Clarke SJ, Chua W, Moore M, et al. Use of inflammatory markers to guide cancer treatment. Clin Pharmacol Ther. 2011;90(3):475–478. doi:10.1038/clpt.2011.122
   PubMed Web of Science ®Google Scholar
• Liao W, Zhang J, Zhu Q, et al. Preoperative neutrophil-to-lymphocyte ratio as a new prognostic marker in hepatocellular carcinoma after curative resection. Transl Oncol. 2014;7(2):248–255. doi:10.1016/j.tranon.2014.02.011
   PubMed Web of Science ®Google Scholar
• Motomura T, Shirabe K, Mano Y, et al. Neutrophil-lymphocyte ratio reflects hepatocellular carcinoma recurrence after liver transplantation via inflammatory microenvironment. J Hepatol. 2013;58(1):58–64. doi:10.1016/j.jhep.2012.08.017
   PubMed Web of Science ®Google Scholar
• Fan W, Zhang Y, Wang Y, Yao X, Yang J, Li J. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of survival and metastasis for recurrent hepatocellular carcinoma after transarterial chemoembolization. PLoS One. 2015;10(3):e0119312. doi:10.1371/journal.pone.0119312
   Web of Science ®Google Scholar
• Tian XC, Liu XL, Zeng FR, Chen Z, Wu DH. Platelet-to-lymphocyte ratio acts as an independent risk factor for patients with hepatitis B virus-related hepatocellular carcinoma who received transarterial chemoembolization. Eur Rev Med Pharmacol Sci. 2016;20(11):2302–2309.
   PubMed Web of Science ®Google Scholar
• Chu MO, Shen CH, Chang TS, et al. Pretreatment inflammation-based markers predict survival outcomes in patients with early stage hepatocellular carcinoma after radiofrequency ablation. Sci Rep. 2018;8(1):16611. doi:10.1038/s41598-018-34543-z
   PubMed Web of Science ®Google Scholar
• Bruix J, Cheng AL, Meinhardt G, Nakajima K, De Sanctis Y, Llovet J. Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: analysis of two phase III studies. J Hepatol. 2017;67(5):999–1008. doi:10.1016/j.jhep.2017.06.026
   PubMed Web of Science ®Google Scholar
• Liu L, Gong Y, Zhang Q, Cai P, Feng L. Prognostic roles of blood inflammatory markers in hepatocellular carcinoma patients taking sorafenib. A systematic review and meta-analysis. Front Oncol. 2019;9:1557. doi:10.3389/fonc.2019.01557
   Web of Science ®Google Scholar
• Byun HK, Kim N, Park S, Seong J. Acute severe lymphopenia by radiotherapy is associated with reduced overall survival in hepatocellular carcinoma. Strahlenther Onkol. 2019;195(11):1007–1017. doi:10.1007/s00066-019-01462-5
   Web of Science ®Google Scholar
• Wolfe AR, Siedow M, Nalin A, et al. Increasing neutrophil-to-lymphocyte ratio following radiation is a poor prognostic factor and directly correlates with splenic radiation dose in pancreatic cancer. Radiother Oncol. 2021;158:207–214. doi:10.1016/j.radonc.2021.02.035
   Web of Science ®Google Scholar
• Wahl DR, Stenmark MH, Tao Y, et al. Outcomes after stereotactic body radiotherapy or radiofrequency ablation for hepatocellular carcinoma. J Clin Oncol. 2016;34(5):452–459. doi:10.1200/JCO.2015.61.4925
   PubMed Web of Science ®Google Scholar
• Sapisochin G, Barry A, Doherty M, et al. Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis. J Hepatol. 2017;67(1):92–99. doi:10.1016/j.jhep.2017.02.022
   PubMed Web of Science ®Google Scholar
• Sapir E, Tao Y, Schipper MJ, et al. Stereotactic body radiation therapy as an alternative to transarterial chemoembolization for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2018;100(1):122–130. doi:10.1016/j.ijrobp.2017.09.001
   PubMed Web of Science ®Google Scholar
• Marciscano AE, Haimovitz-Friedman A, Lee P, et al. Immunomodulatory effects of stereotactic body radiation therapy: preclinical insights and clinical opportunities. Int J Radiat Oncol Biol Phys. 2021;110(1):35–52. doi:10.1016/j.ijrobp.2019.02.046
   Web of Science ®Google Scholar
• Wild AT, Herman JM, Dholakia AS, et al. Lymphocyte-sparing effect of stereotactic body radiation therapy in patients with unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys. 2016;94(3):571–579. doi:10.1016/j.ijrobp.2015.11.026
   PubMed Web of Science ®Google Scholar
• Lo CH, Lee HL, Hsiang CW, et al. Pretreatment neutrophil-to-lymphocyte ratio predicts survival and liver toxicity in patients with hepatocellular carcinoma treated with stereotactic ablative radiation therapy. Int J Radiat Oncol Biol Phys. 2021;109(2):474–484. doi:10.1016/j.ijrobp.2020.09.001
   PubMed Web of Science ®Google Scholar
• Lo CH, Liu MY, Lee MS, et al. Comparison between Child-Turcotte-Pugh and albumin-bilirubin scores in assessing the prognosis of hepatocellular carcinoma after stereotactic ablative radiation therapy. Int J Radiat Oncol Biol Phys. 2017;99(1):145–152. doi:10.1016/j.ijrobp.2017.04.036
   PubMed Web of Science ®Google Scholar
• Huang WY, Jen YM, Lee MS, et al. Stereotactic body radiation therapy in recurrent hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2012;84(2):355–361. doi:10.1016/j.ijrobp.2011.11.058
   PubMed Web of Science ®Google Scholar
• Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52–60. doi:10.1055/s-0030-1247132
   PubMed Web of Science ®Google Scholar
• Navarro-Martin A, Galiana IL, Berenguer Frances MA, et al. Preliminary study of the effect of stereotactic body radiotherapy (SBRT) on the immune system in lung cancer patients unfit for surgery: immunophenotyping analysis. Int J Mol Sci. 2018;19(12):3963. doi:10.3390/ijms19123963
   PubMed Web of Science ®Google Scholar
• Zhuang Y, Yuan BY, Hu Y, et al. Pre/post-treatment dynamic of inflammatory markers has prognostic value in patients with small hepatocellular carcinoma managed by stereotactic body radiation therapy. Cancer Manag Res. 2019;11:10929–10937. doi:10.2147/CMAR.S231901
   PubMed Web of Science ®Google Scholar
• Plowman PN. The effects of conventionally fractionated, extended portal radiotherapy on the human peripheral blood count. Int J Radiat Oncol Biol Phys. 1983;9(6):829–839. doi:10.1016/0360-3016(83)90008-1
   PubMed Web of Science ®Google Scholar
• Falcke SE, Ruhle PF, Deloch L, Fietkau R, Frey B, Gaipl US. Clinically relevant radiation exposure differentially impacts forms of cell death in human cells of the innate and adaptive immune system. Int J Mol Sci. 2018;19(11):3574. doi:10.3390/ijms19113574
   Web of Science ®Google Scholar
• Cupp MA, Cariolou M, Tzoulaki I, Aune D, Evangelou E, Berlanga-Taylor AJ. Neutrophil to lymphocyte ratio and cancer prognosis: an umbrella review of systematic reviews and meta-analyses of observational studies. BMC Med. 2020;18(1):360. doi:10.1186/s12916-020-01817-1
   PubMed Web of Science ®Google Scholar
• Micaela R, Lucas C, Franco C, Federico C, Agustin D, David S. Dynamic perioperative variation of neutrophil-to-lymphocyte ratio as an independent prognosis factor following lobectomy for NSCLC. Updates Surg. 2021;73(4):1567–1574. doi:10.1007/s13304-020-00936-x
   PubMed Web of Science ®Google Scholar
• Min KW, Kwon MJ, Kim DH, et al. Persistent elevation of postoperative neutrophil-to-lymphocyte ratio: a better predictor of survival in gastric cancer than elevated preoperative neutrophil-to-lymphocyte ratio. Sci Rep. 2017;7(1):13967. doi:10.1038/s41598-017-13969-x
   PubMed Web of Science ®Google Scholar
• Chua W, Charles KA, Baracos VE, Clarke SJ. Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. Br J Cancer. 2011;104(8):1288–1295. doi:10.1038/bjc.2011.100
   PubMed Web of Science ®Google Scholar
• Ameratunga M, Chenard-Poirier M, Moreno Candilejo I, et al. Neutrophil-lymphocyte ratio kinetics in patients with advanced solid tumours on phase I trials of PD-1/PD-L1 inhibitors. Eur J Cancer. 2018;89:56–63. doi:10.1016/j.ejca.2017.11.012
   PubMed Web of Science ®Google Scholar
• Dan J, Zhang Y, Peng Z, et al. Postoperative neutrophil-to-lymphocyte ratio change predicts survival of patients with small hepatocellular carcinoma undergoing radiofrequency ablation. PLoS One. 2013;8(3):e58184. doi:10.1371/journal.pone.0058184
   PubMed Web of Science ®Google Scholar
• Hong YM, Yoon KT, Hwang TH, Heo J, Woo HY, Cho M. Changes in the neutrophil-to-lymphocyte ratio predict the prognosis of patients with advanced hepatocellular carcinoma treated with sorafenib. Eur J Gastroenterol Hepatol. 2019;31(10):1250–1255. doi:10.1097/MEG.0000000000001405
   PubMed Web of Science ®Google Scholar
• Choi WM, Kim JY, Choi J, et al. Kinetics of the neutrophil-lymphocyte ratio during PD-1 inhibition as a prognostic factor in advanced hepatocellular carcinoma. Liver Int. 2021;41(9):2189–2199. doi:10.1111/liv.14932
   Web of Science ®Google Scholar
• Cousins MM, Morris E, Maurino C, et al. TNFR1 and the TNFalpha axis as a targetable mediator of liver injury from stereotactic body radiation therapy. Transl Oncol. 2021;14(1):100950. doi:10.1016/j.tranon.2020.100950
   Web of Science ®Google Scholar
• Ng SSW, Zhang H, Wang L, Citrin D, Dawson LA. Association of pro-inflammatory soluble cytokine receptors early during hepatocellular carcinoma stereotactic radiotherapy with liver toxicity. NPJ Precis Oncol. 2020;4:17. doi:10.1038/s41698-020-0124-z
   PubMed Web of Science ®Google Scholar
• Najar Nobari N, Shahidi Dadras M, Nasiri S, Abdollahimajd F, Gheisari M. Neutrophil/platelet to lymphocyte ratio in monitoring of response to TNF-alpha inhibitors in psoriatic patients. Dermatol Ther. 2020;33(4):e13457. doi:10.1111/dth.13457
   PubMed Web of Science ®Google Scholar